You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Progen Pharmaceuticals Limited (PGL) is a Brisbane-based biotechnology company specialising in the research and development of potential biopharmaceutical therapeutics for treating cancer (PI-88) and primary liver cancer (PI-166), a devastating disease with few treatment options available to patients.
Company History
Progen was established in 1990, originally focused on the manufacture and supply of molecular biology reagents and kits. Since then, Progen has diversified into the research and development of biopharmaceuticals and contract manufacture. Since its listing in December 1995 at $0.30 per share, the company has focused its activities on its lead compound, an anti-cancer drug called PI-88. PGL was renamed to its current name in April 2007.
Differentiating Factor
PGL specialises in understanding the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is currently in Phase II clinical trials for malanoma, liver and lung cancer while PI-166 is in Phase Ib clinical trials.
Major Customers & Competitors
As a biotechnology R&D company, PGL has no customers as such. Nor does it have competition in the true sense of the word, for although there are many biotech firms researching a therapy for cancer, there are many varieties of cancer, and the sufferers have many different needs.
Financial Summary
Year to Jun
NPAT Rep $M
NPAT1 Adj $M
EPS c
EPS chg %
PER x
PER rel All Ords x
PER rel Sector x
DPS c
Yield %
Franking %
ROE %
2004A
(4.8)
(5.3)
(14.7)
n/a
(3.5)
(0.1)
0.0
0.0
0.0
0
-32.3
2005A
(5.9)
(5.9)
(16.6)
n/a
(3.1)
(0.1)
(0.1)
0.0
0.0
0
-28.5
2006A
(7.6)
(7.6)
(18.8)
n/a
(2.7)
(0.1)
(0.1)
0.0
0.0
0
-35.4
2007A
(22.5)
(22.5)
(50.2)
n/a
(1.0)
n/a
n/a
0.0
0.0
0
-39.1
2008A
(26.1)
(26.1)
(43.3)
n/a
(1.2)
n/a
n/a
0.0
0.0
0
-30.5
2009A
(5.5)
(5.5)
(10.0)
n/a
(5.1)
n/a
n/a
0.0
0.0
0
-10.4
1NPAT is normalised by removing non-recurring items and goodwill. All the above statistics are derived from normalised earnings.
Sydney Morning Herald 10/03/2010 | THE chief executive of the Bank of Queensland, David Liddy, is looking to pull off one more big acquisition before he brings down the curtain on a banking career of 40 years, including 10 at the helm of the Brisbane institution.
The Age 10/03/2010 | THE $9.6 billion push by AXA Asia Pacific's major shareholder to get its hands on the Australian fund manager's Asian operations has been reinforced by a surge in new business in the region.
Sydney Morning Herald 10/03/2010 | THE $9.6 billion push by AXA Asia Pacific's major shareholder to get its hands on the fund manager's Asian operations has been reinforced by a surge in new business in the region since the Australian company declared its full-year results.
The Age 10/03/2010 | ANZ has confirmed it has settled a legal dispute with Steve Targett, the former head of the bank's institutional business, who sued for $57 million after being passed over as chief executive.
The Age 10/03/2010 | THE jobs market has turned white hot, with newspaper job ads being placed at a rate not seen since the onset of the financial crisis.
$ 0.510
